U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07775482) titled 'Finerenone for AKI: a Multicenter, Randomized, Placebo-Controlled Feasibility Pilot Trial' on Aug. 17.
Brief Summary: This study is testing whether finerenone, when compared to placebo, is a tolerable and safe intervention when administered in patients with acute kidney injury (AKI). This study will explore whether finerenone can mitigate the risk of transitioning to chronic kidney disease following a moderate to severe AKI. Participants will be randomly assigned to receive either finerenone or a placebo, once daily for up to 45 days, in addition to their standard care. The study will monitor for side effects such as serum potassium...